This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Regulatory / Roche FDA Approves PTEN Assay
Regulatory FDA approval

Roche FDA Approves PTEN Assay

Analysis based on 9 articles · First reported Jun 12, 2026 · Last updated Jun 12, 2026

Sentiment
70
Attention
4
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The FDA approval of Roche's diagnostic assay is expected to positively impact the pharmaceutical and biotechnology markets by enabling more targeted treatments for prostate cancer. This could lead to increased sales for AstraZeneca's TRUQAP and strengthen Roche's position in companion diagnostics.

Pharmaceuticals Biotechnology Healthcare
Event Summary

Roche announced that its VENTANA PTEN (SP218) RxDx Assay received U.S. Food and Drug Administration approval. This assay is the first immunohistochemistry companion diagnostic test to identify PTEN protein loss in prostate adenocarcinoma tumors. This approval allows patients with PTEN-deficient prostate cancer to be eligible for combination treatment with AstraZeneca's targeted therapy TRUQAP (capivasertib). The diagnostic tool addresses an unmet medical need, as PTEN protein loss is linked to faster disease progression and reduced effectiveness of standard treatments. Roche Holding — Foundation Medicine, an affiliate of Roche, will be using this assay.

Entities Involved
subs
Roche Holding — Foundation Medicine
Roche Holding — Foundation Medicine, an affiliate of Roche, is a laboratory utilizing the VENTANA PTEN (SP218) RxDx Assay to help identify patients with PTEN protein loss.
Importance 40.0 Sentiment 50.0
per
Matt Sause
Matt Sause, CEO of Roche Diagnostics, commented on the significance of the FDA approval for providing new therapeutic options for prostate cancer patients.
Importance 20.0 Sentiment 50.0
stock
Roche
Importance 0.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
Importance 0.0 Sentiment 0.0
stock
AstraZeneca
Importance 0 Sentiment 0
Relationships
Matt Sause related ↔ Roche
Roche related ↔ United States — Food and Drug Administration
Roche related ↔ AstraZeneca
United States — Food and Drug Administration related ↔ AstraZeneca
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.